Market
Which country will first commercially launch Zunveyl in Asia-Pacific by end of 2025?
2
Resolution / Starting Odds
China • 25%
Australia • 25%
New Zealand • 25%
Other Asia-Pacific country • 25%
Press releases or announcements from Alpha Cognition or local regulatory bodies
Story
Alpha Cognition Secures $44 Million Licensing Deal for Alzheimer's Drug Zunveyl in China, Including $6 Million Upfront
Jan 8, 2025, 01:48 PM
Alpha Cognition Inc. has announced a $44 million exclusive licensing agreement for the development and commercialization of Zunveyl, an FDA-approved treatment for mild-to-moderate Alzheimer’s disease, in China. The deal includes a $6 million upfront payment and covers regions including Asia (excluding Japan), Australia, and New Zealand. Zunveyl, also known as benzgalantamine, is anticipated to address neuroinflammation associated with Alzheimer’s disease. This agreement was made with China Medical System, as Alpha Cognition aims to expand its market presence in the Asia-Pacific region.
View original story
Similar markets
United Kingdom • 25%
Other • 25%
Australia • 25%
European Union • 25%
Europe • 25%
North America • 25%
China • 25%
Other • 25%
Less than 5 • 25%
11 to 15 • 25%
More than 15 • 25%
5 to 10 • 25%
China • 25%
United States • 25%
Other • 25%
European Union • 25%
Rest of the World • 25%
Europe • 25%
North America • 25%
Asia-Pacific • 25%
Japan • 25%
South Korea • 25%
China • 25%
Other • 25%
Europe • 25%
North America • 25%
Asia • 25%
Other • 25%
Japan • 25%
France • 25%
Germany • 25%
Other • 25%
Japan • 25%
China • 25%
India • 25%
Other • 25%
Other • 25%
Canada • 25%
United Kingdom • 25%
Australia • 25%
China • 25%
United States • 25%
Europe • 25%
Other • 25%
North America • 25%
Southeast Asia • 25%
Europe • 25%
Other regions • 25%